Plain-English translation of NCT03970447 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Glioblastoma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
GBM AGILE is a large international study testing several new medications and treatment combinations for glioblastoma, a serious type of brain cancer. The trial enrolls patients with newly diagnosed disease or those whose cancer has returned after prior treatment. The study uses a flexible design that learns over time—if one treatment appears to work better, more patients are assigned to it, and less promising treatments may be stopped early.
Glioblastoma is a difficult cancer to treat, and current standard treatments don't work well enough for many patients. This study exists to find better medication options and figure out which treatments work best for different patient subtypes, rather than using a one-size-fits-all approach.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either the standard treatment (radiation therapy plus chemotherapy) or one of several experimental medication arms being tested. You will visit the trial site regularly for check-ups, scans, and blood tests to monitor how you are responding. The exact schedule depends on which arm you are assigned to, but participation typically involves ongoing visits over many months while you receive the medication.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
United States